<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849273</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0131-01</org_study_id>
    <nct_id>NCT04849273</nct_id>
  </id_info>
  <brief_title>A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC</brief_title>
  <official_title>A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turning Point Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turning Point Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1/2, first-in-human, open-label study to evaluate the safety, tolerability, PK, and&#xD;
      efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or&#xD;
      metastatic non-small cell lung cancer (NSCLC). The study consists of two portions: 1) Phase 1&#xD;
      dose escalation, and 2) Phase 2 efficacy evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 Dose Escalation: To evaluate the overall safety profile, efficacy of TPX-0131 in&#xD;
      pretreated subjects with ALK+ advanced or metastatic NSCLC.&#xD;
&#xD;
      Phase 2 Efficacy Evaluation: To determine the safety and anti-tumor efficacy of TPX-0131 in&#xD;
      defined cohorts of subjects with advanced or metastatic ALK+ NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0131</measure>
    <time_frame>Within 28 days of the first TPX-0131 dose for each patient</time_frame>
    <description>Evaluate the safety and tolerability of TPX-0131</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the Recommended Phase 2 Dose</measure>
    <time_frame>Approximately 22 months</time_frame>
    <description>Determine the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of TPX-0131</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the objective response rate (ORR)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the preliminary efficacy by the ORR in defined cohorts with ALK+ advanced or metastatic NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the DOR of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the TTR of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the CBR of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial tumor response</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the intracranial tumor response in subjects with measurable brain metastases, as determined by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the PFS of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the efficacy and safety of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Evaluate the overall safety profile of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS Progression-Free Survival (CNS-PFS)</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Determine the CNS-PFS in patients with measurable brain metastases using Modified RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration) of TPX-0131</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
    <description>Evaluate the maximum plasma concentration of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under plasma concentration time curve) of TPX-0131</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
    <description>Determine the AUC of TPX-0131</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life - Core Quality of Life Questionnaire</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Estimate the effect of TPX-0131 on patient-reported outcomes using the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire to assess subject's ability to complete 30 daily activities. The scale, from 1 to 4 (1 = not difficult to 4 = very difficult), indicates the level of difficulty to complete a task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life - Lung Cancer Quality of Life Questionnaire</measure>
    <time_frame>Approximately 44 months</time_frame>
    <description>Estimate the effect of TPX-0131 on patient-reported outcomes, using the Lung Cancer Quality of Life Questionnaire asks questions related to 13 specific lung cancer symptoms. The scale, from 1 to 4&#xD;
(1 = not often to 4 = very often), indicates the frequency of symptoms experienced in a given week.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>NSCLC</condition>
  <condition>Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <condition>ALK Gene Mutation</condition>
  <arm_group>
    <arm_group_label>TPX-0131</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.&#xD;
The Phase 2 part of the study will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-0131</intervention_name>
    <description>Oral TPX-0131 tablets</description>
    <arm_group_label>TPX-0131</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 (or as required by local regulation).&#xD;
&#xD;
          -  Histological or cytological confirmation of advanced/metastatic ALK+ NSCLC.&#xD;
&#xD;
          -  Pretreated with up to three prior lines of an ALK TKI treatment, including at least&#xD;
             one prior line of a second or third-generation ALK TKI (alectinib, brigatinib,&#xD;
             ensartinib, or lorlatinib) in Phase 1.&#xD;
&#xD;
          -  ECOG performance status ≤ 1.&#xD;
&#xD;
          -  Existence of measurable or evaluable disease (according to Response evaluation&#xD;
             criteria in solid tumors [RECIST v1.1] criteria).&#xD;
&#xD;
          -  Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal&#xD;
             carcinomatosis are eligible.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within four weeks of the start of TPX-0131 treatment.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Any of the following cardiac criteria:&#xD;
&#xD;
               -  Mean resting corrected QT interval (QTc) &gt; 470 msec obtained from three ECGs and&#xD;
                  any factors that increase the risk of QTc prolongation or arrhythmic events&#xD;
&#xD;
               -  Any clinically important abnormalities in rhythm, conduction, or morphology of&#xD;
                  resting ECG&#xD;
&#xD;
          -  Known clinically significant active infections not controlled with systemic treatment&#xD;
             (bacterial, fungal, viral including HIV positivity).&#xD;
&#xD;
          -  Gastrointestinal disease or other malabsorption syndromes that would impact drug&#xD;
             absorption.&#xD;
&#xD;
          -  Subjects being treated with or anticipating the need for treatment with strong CYP3A4&#xD;
             inhibitors or inducers.&#xD;
&#xD;
          -  Subjects with current or anticipated need for drugs that are sensitive CYP2C9&#xD;
             substrates with narrow therapeutic indices.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Park, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Turning Point Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Park, M.D</last_name>
    <phone>(858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Health - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fa-Chyi Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Jiyeong Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Awad, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin E. Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander I. Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blacktown Cancer and Hematology Centre</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adnan Nagrial, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Benjamin Solomon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Michael Millward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>Advanced/metastatic disease</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>Advanced solid tumor</keyword>
  <keyword>ALK gene fusion</keyword>
  <keyword>ALK inhibitor</keyword>
  <keyword>TPX-0131</keyword>
  <keyword>ALK TKI</keyword>
  <keyword>ALK Tyrosine Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

